Congenital Ichthyosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Congenital recessive ichthyoses manifest as a diverse set of disorders marked by skin scaling and a thickened stratum corneum. Clinically, they present with symptoms such as red, dry, and rough skin, often adorned with large or fine white scales. Variability exists in scale appearance, ranging from delicate white to dark brown with deep cracks. The palms and soles may exhibit excessive thickening of the skin. These manifestations are mutations in genes like TGM1, which encodes transglutaminase 1, pivotal in forming the epidermal cornified cell envelope. Additionally, ABCA12, ALOX12B, ALOXE3, and CYP4F22 genes play lipid metabolism and transport roles. Complications can arise from severe cases, including skin dryness, tightness, and inelasticity, leading to cracking and fissures, particularly problematic in movement and daily tasks. Treatment of ichthyosis primarily focuses on hydration, lubrication, and keratolysis, achievable through topical agents or systemic retinoids for keratolytic effects. In cases prone to skin infections, antimicrobials are commonly employed. Despite advancements, therapy remains challenging, with some deeming current options as laborious and moderately effective, coupled with notable side effects. Progress in treating severe neonatal ichthyosis is notable, yet challenges persist, notably in addressing anhidrosis and ectropion, which are often resistant to therapy.
- Prevalence estimates indicate 1 to 2 cases per 275,000 individuals in the USA.
Thelansis’s “Congenital Ichthyosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Ichthyosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Congenital Ichthyosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Congenital Ichthyosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment